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I
n the past two decades, the imaging and
therapeutic capabilities of nanoparticles
(NPs) have demonstrated high useful-
ness for biomedical applications.1,2 Indepen-
dent of their chemical composition, shape, or
charge, most NPs between 20 and 200 nm
are partially eliminated by the liver, con-
tributing to retention within the reticuloen-
dothelial system (RES), which includes
macrophages and macrophage precursors,
specialized endothelial cells that line the
liver sinusoids, bone marrow, and spleen.
Long-term retention of NPs could induce
toxicity.35 It is sensible to assume that bio-
distribution, accumulation, metabolism, and
excretion of NPs will aﬀect the toxicity of this
nanoagent in the organism. The ability of the
nanoparticles to aﬀect the normal physiology
as well as the normal structure of organs and
tissues depends on physiochemical param-
eters such as particle size, shape, surface
charge, chemistry, composition, and stability.
Thus, research has focused either on the
development of biodegradable NPs or on
NPs with a hydrodynamic diameter (HD)
smaller than 6 nm to prevent any undesired
accumulation andpromote renal clearance.6,7
However, an HD smaller than the theoretical
glomerular ﬁltration limit (<6 nm)8 may not
be suﬃcient to promote glomerular ﬁltration.
Ultrasmall gold NPs (D < 2 nm) have been
reported to be either mainly excreted
through the liver several days after injection9
or rapidly eliminated via the kidneys.10
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ABSTRACT We previously reported the synthesis of gadolinium-based nanoparticles (NPs) denoted
AGuIX (activation and guiding of irradiation by X-ray) NPs and demonstrated their potential as an MRI
contrast agent and their eﬃcacy as radiosensitizing particles during X-ray cancer treatment. Here we
focus on the elimination kinetics of AGuIX NPs from the subcellular to whole-organ scale using original
and complementary methods such as laser-induced breakdown spectroscopy (LIBS), intravital two-
photon microscopy, inductively coupled plasma optical emission spectrometry (ICP-OES), transmission
electron microscopy (TEM), and electrospray ionization mass spectrometry (ESI-MS). This combination of
techniques allows the exact mechanism of AGuIX NPs elimination to be elucidated, including their retention
in proximal tubules and their excretion as degraded or native NPs. Finally, we demonstrated that systemic
AGuIX NP administration induced moderate and transient eﬀects on renal function. These results provide
useful and promising preclinical information concerning the safety of theranostic AGuIX NPs.
KEYWORDS: nanoparticle . gadolinium . theranostic . two-photon microscopy . laser-induced breakdown spectroscopy .
renal function . toxicity
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Considering the use of MRI contrast agents, super-
magnetic iron oxide nanoparticles (SPIONs) or gadoli-
nium-basedMRI agents, the process of imaging should
be a safe diagnostic procedure. SPIONs are often
eliminated through both kidney and liver, whichmight
lead to RES retention or migration of the particles
through the organism.1113 This speciﬁc retention in
the liver is sometimes the purpose of the SPION,
dedicate to hepatic imaging. Nevertheless, the SPIONs
family, including their byproducts, might trigger an
immunological or an inﬂammatory response, pro-
cesses that should be investigated before clinical
transfer.4,14 The gadolinium-basedMRI contrast agents
were approved by the FDA and European agencies in
the early 2000s. Among them, some nanoparticles
were correlated with high (>0.1 case/million appli-
cations) relative frequency of nephrogenic systemic
ﬁbrosis (NSF).1518 This serious and sometimes fatal
disease has been related to transmetalation which
leads to the release of free gadolinium from the
chelates in the body, due to previous renal dysfunction,
extensive administration of gadolinium, and/or coex-
istence of disease such as inﬂammation.19 The trans-
metalation occurs particularly with acyclic chelates.
Therefore, the guidelines issued by the regulatory
authorities allowed a reduction of the number of new
cases of NSF to almost zero; these guidelines include
providing patients a possible beneﬁt that outweighs
the risk, limiting the amount of injected gadolinium,
and measuring the glomerular ﬁltration rate prior to
the administration of Gd-chelate.20
We previously developed original polysiloxanes
nanoparticles containing gadolinium ions (Gd) called
AGuIX (activation and guiding of irradiation by X-ray)
NPs, with an HD of approximately 3 nm for therapeutic
application including radiosensitization andmultimodal
imaging.2,2123 The process of elimination and safety
of AGuIX NPs has to be evaluated as a part of the
preclinical evaluation. AGulXNPs aremainly eliminated
through the kidneys. Twenty-four hours after injection,
less than 0.2% of the injected dose of radiolabeled
particles was observed in any other organ.2,2426 How-
ever, the mechanism of AGuIX elimination remained
unclear. To determine the exact mechanism under-
lying of AGuIX elimination, the study was determined
in a mice model. The AGuIX NPs were administered
intravenously (IV) tomice prior to investigation of renal
function. Using either native or ﬂuorescently labeled
particles, we combined intravital and ﬁxed-sample
explorations at the subcellular to whole-organ scale
using two-photon microscopy, inductively coupled
plasma optical emission spectrometry (ICP-OES), trans-
mission electron microscopy (TEM), and a method
we have developed for biological tissue application,
laser-induced breakdown spectroscopy (LIBS). Expo-
sure to Gd-containing agents was associated with the
occurrence of NSF; such pathologymight be due to the
release of Gd from the agent and seems to occur for
acyclic agents.27 However, the AGuIX NPs possess
cyclic chelating agents and exhibit a very strong com-
plexation constant (logβ110 = 24.78), which prevent Gd
release.21 In this study, we analyzed renal function,
identiﬁed the NP's metabolites in urine samples by
electrospray ionization mass spectrometry (ESI-MS),
and obtained evidence of the safe biodegradation
of the NP in vivo. In addition, histological analysis
of kidney sections performed after repeated treatment
with AGuIX conﬁrmed the low impact of multiple
injections on renal function and microstructure.
PRELIMINARY RESULTS: BRIEF DESCRIPTION OF
THE NANOPARTICLE
The Gd-based AGuIX NPs were developed and de-
signed for theranostic approaches in cancer radio-
therapy.2,21,23 AGuIX NPs are composed of a polysilox-
ane network surrounded by Gd chelates covalently
grafted to the polysiloxane inorganic matrix and are
synthesized by a top-down process (Figure 1A and
Supporting Information).2,21 These NPs exhibit an ul-
trasmall size, with an HD of approximately 3 ( 0.1 nm
(Figure 1B). The complexation constant (log β110) of
these NPs for Gd is 24.78.21 This value is very close to
the complexation constant of the commercial agent
DOTAREM (25.58) determined under the same condi-
tions. AGuIX NPs contain approximately 10 chelates per
NP, with a mass of approximately 9 kDa. A representa-
tive MSmeasurement and the corresponding deconvo-
lution of native full NPs are shown in Figure 1C.28 In
human serum, the particles are slowly degraded with
time, in a dose-dependent manner, until reaching an
equilibrium of stability (Figure 1D). This partial degrada-
tion occurs on the polysiloxane matrix level, with the
hydrolysis of the SiOSi bonds and without releasing
any of the gadolinium ions.28
RESULTS
I. AGuIX Renal Kinetics and Mechanism of Elimination. Pre-
vious studies of the Gd-based AGuIX NP indicated both
rapid kidney accumulation and renal clearance of the
particles, as expected for their small size.2,25,29 Twenty-
four hours after intravenous (IV) injection, a fraction of
the injected dose (ID, approximately 10% ID/g) was still
observed in the kidney, whereas all other organs
exhibited less than 0.2% of the total ID. Different
techniques employing both native and fluorescently
labeled NPs were employed to precisely investigate
and understand the renal elimination of AGuIX NPs
after injection of a therapeutic dose (8 μmol of Gd in
mice). These techniques present simultaneously ad-
vantages and drawbacks (see Supporting Information,
Table S1) as well as different resolutions and sensitiv-
ities, resulting in a strong complementarity.
Whole-Organ Imaging Using Laser-Induced Break-
downSpectroscopy (LIBS). LIBS scanning imaging studies
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were first performed at the entire organ scale. Label-free
NPs were injected IV inmice. Kidneys were subsequently
collected, epoxy-embedded, and sliced for LIBS analysis.
We recently adapted this technique to image and quan-
tify multichemical elements in biological tissues (see
Supporting Information, Figure S1).3032 This novel
approach possesses an all-optical design and allows
multielemental scanning imaging and quantification
with a maximal spatial resolution of 10 μm.
To evaluate the kinetics of AGuIX NP elimination,
kidneys were collected at diﬀerent elapsed times after
AGuIX NP administration (ranging from5min to 1week)
and imaged for Gd, a major element of AGuIX NPs
(Figure 2). AGuIX NPs rapidly reached the kidneys, as
indicated by the detection of the Gd signal as early as
5 min after IV injection, indicating that the NPs were
distributed throughout the organism and reached the
kidney during the ﬁrst passage of blood through the
organ. As for all components ﬁltered by the kidneys,
AGuIX NPs were ﬁrst observed in close proximity to the
cortex region, where the Bowman's capsules are located
and in excellent agreement with previous nuclear ima-
ging studies,2 before diﬀusing throughout the entire
organ (see Supporting Information, Figure S2). The elimi-
nation process resulted in the production of an increas-
ing Gd signal that reached a maximum at 4 h postadmi-
nistration, followed by a subsequent decrease. One
week after injection, most of the signal had been
cleared, indicating eﬀective particle elimination from
the body via urine. One week after IV injection, a weak
Gd signal was still observed; this could be attributable to
a speciﬁc entrapment of the particles in the tubules. We
alsoperformedhigh-resolution screeningof a kidney sam-
pled 3 h after IV injection of AGuIX NPs. As indicated in
Figure 3, the Gd signal was heterogeneous in the cortex
region, suggesting a speciﬁc accumulation in this region.
Figure 1. Gd-basedAGuIXNP. (A) The components of AGuIXNPs are schematically represented as follows: Gd atoms chelated
by DOTA derivatives are indicated in green, and the polysiloxanematrix comprisingmainly silicon and oxygen is indicated in
gray and red, respectively. The averagemolecularmass of aAGuIXNP is 8.7( 0.3 kDa,with a highGd content (15wt%). AGuIX
NP has an average chemical formula Gd10Si40C200N50O150Hx. (B) The HD distribution of AGuIX NPs as determined by DLS
indicates a size of 3 nm. (C) ESI-MS measurements as recorded on the global spectrum. The inset indicates the spectrum
generated after deconvolution with a multiplicative correlation algorithm. (D) Temporal evolution of the longitudinal
relaxivity (r1) of the particles, related to their stability, in human serum. The curve ﬁttings, represented by lines, were
determined by a monoexponential decay model.
Figure 2. Quantitative imaging of Gd and sodium (Na) by LIBS, related to the distribution of AGuIX NPs in the kidney as a
function of elapsed time after administration. Images have been recorded with a spatial resolution of 40 μm. See also
Supporting Information, Table S1.
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Dynamic Approach of the Cortex Uptake. To prevent
the use of fixative during the determination of the
elimination kinetics, we used intravital two-photon
microscopy analysis of functional kidneys. Intravital
two-photon microscopy is a high-resolution, real-time,
fluorescence imaging technique that permits the anal-
ysis of structural and functional changes in a given
tissue at the single cell to the millimeter level.33,34 To
visualize the renal elimination of the NPs, fluorescent
Rhodamine B-labeled AGuIX NPs were injected IV in
mice 5min to 2 weeks prior to two-photonmicroscopy
imaging. During anesthesia, the kidney was main-
tained in a humidified environment at 37 C outside
themouse body to eliminatemovement due to breath-
ing andmaintain kidney function and blood circulation
and placed under the microscope objective (see Sup-
porting Information, Figure S3). A mix of fluorescent
dyes was also injected IV to better localize both nuclei
and vessels (counterstaining).
Rhodamine B-labeled AGuIX NPs reached the kid-
ney as soon as 5 min after injection, as indicated by a
diﬀuse red signal observed in both the blood vessels
and the tubules (Figure 4). In vessels, the colocalization
of FITC-dextran (70 kDa; green) with Rhodamine B (red)
produced a high yellow signal. The NPs were rapidly
extravasated and reached the tubules 1 h after injec-
tion, as indicated by precise red spots inside the tubule
cells. For all investigations performed after longer than
1 h postinjection, a negligible signal was detected in
the nuclei and the vessels, indicating eﬃcient ﬁltration
of the particles. Similar results were observed at 4 and
48 h postinjection, with a high red ﬂuorescent signal
in the cytoplasm of tubule cells. At all time points
between 1 and 48 h, some of the tubules appeared to
contain the highest number of particles, as previously
observed by LIBS; however, without more speciﬁc
labeling, intravital microscopy analysis could not reveal
whether this uptakewaspredominant in theproximal or
distal convoluted tubules. One week after administra-
tion, AGuIX was poorly detected in some tubules,
whereas others appeared completely empty. The renal
elimination of AGuIX by 2weeks after injectionwas indi-
cated by a very weak red signal similar to that observed
in the control (Supporting Information, Figure S4a).
Figure 3. High-deﬁnition image of Gd obtained by LIBS. The kidney was screened with a spatial resolution of 10 μm (80 000
pixels), currently the highest resolution that might be obtained using LIBS. The heterogeneous distribution of Gd in the
kidney cortex is readily apparent 4 h postinjection.
Figure 4. Two-photon microscopy of mice kidneys, from 5 min to 2 weeks after a single injection of 200 μL of Rhodamine
B-AGuIX (red) at 40 mM Gd. The nucleus and vessels were stained by injecting 50 μL of a mixture of Hoechst 33342 (blue) and
FITC-Dextran70kDa (green) 5minbefore acquisition. The control conditionwasobtainedafter injectionof stainingmixtureonly
(Hoechst 33342 and FITC-Dextran). Scale bar: 20 μm.Also see Supporting Information, Figure S5 for 5min to 1 h in vivo kinetics.
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Replacement of Rhodamine B with FITC had no eﬀect on
the kinetics (also seeSupporting Information, FigureS4b).
Nanoparticle’s Pharmacokinetic. The elimination
kinetics were quantified in the blood, the liver, the
spleen, and the kidneys (Figure 5). The biodistribution
profiles of the kidney obtained by LIBS and intravital
microscopy were also compared to the ones obtained
by inductively coupled plasma-optical emission spec-
trometry (ICP-OES). As demonstrated by Figure 5d, the
kinetics of uptake and elimination determined by two-
photon microscopy and LIBS were in accordance with
the values determined by ICP-OES.35 For more repre-
sentative results, ICP-AES was used to analyze the
kidneys of three animals, including the contralateral
kidney of the kidney used in the LIBS experiments.
The kinetics of accumulation and elimination de-
termined by the three methods were in accordance
and indicated a rapid inﬂow of AGuIX as soon as 5 min
postinjection, a maximum peak after 4 h and a slow
decrease until quasi-complete elimination 2 weeks
after injection. Prior sample preparation was required
prior to the LIBS experiments, including vascular perfu-
sion of the kidney by a ﬁxative that removed and
replaced the blood. This step might explain the diﬀer-
ence observed in the ﬁrst minutes postinjection. One
and two weeks post injection, the data obtained by
two-photon microscopy and ICP-OES were signiﬁcantly
diﬀerent, possibly due to the limitations of ﬂuores-
cence microscopy, that is, the analysis of the surface of
the kidney (300 μm depth), autoﬂuorescence of the
tissue, and high probability of enzymatic degradation
of the labeled particle compared to the high sensitivity
of the ICP-OES method. At 48 h postinjection, two-
photonmicroscopy analysis revealed a heterogeneous
distribution of AGuIX NPs, as indicated by a very
high standard deviation (Figure 4). Nevertheless, the
kinetics observed using the three diﬀerent methods
were highly comparable and complementary.
Investigation at the Cell Level Using Transmission
Electron Microscopy (TEM). As observed in the pre-
vious experiments (Figures 3 and 4), some tubules
retained particles for several days, whereas others
tubules did not. To identify the type of convoluted
tubules implicated in this specific retention in the renal
cortex, TEM was used to analyze samples collected
5 min to 2 weeks postinjection. As demonstrated in
Figure 6, a large quantity of particles was detected as
early as 5 min after IV injection in both proximal and
distal convoluted tubules. Similar results were ob-
served 1 h after AGuIX NP administration. The samples
collected 1 week after IV injection revealed a smaller
quantity of particles, as indicated by the small number
of vacuoles present in the proximal tubules, whereas in
the distal tubules, particles were rarely detected. This
Figure 5. Evaluation of nanoparticle's kinetics of distribution. The nanoparticle's half-life was determined in (a) blood,
(b) liver, and (c) spleen. (d) Direct comparison of the quantitative and relative data obtained after LIBS (black), and ICP-OES
(green) experiments (both expressed as %ID/g) or two-photon microscopy (relative % vs 4 h, red), for kidney.
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specific retention in the proximal tubules under phy-
siological conditions has been described, and the
filtration process may occur for several days before
excretion.36 Finally, 2 weeks after injection, limited
AGuIX aggregates were observed, although most of
the particles were eliminated from both the proximal
and distal tubules.
In summary, the results obtained by the diﬀerent
techniques used to determine the kinetics of AGuIX NP
elimination were similar and indicated a rapid accu-
mulation of AGuIX NPs in the kidneys from the ﬁrst
minutes to approximately 4 h postinjection. This accu-
mulation was mainly observed in the proximal con-
voluted tubules, where some particles remained
entrapped for several days after IV injection before
excretion in urine.
II. AGuIX NP Biodegradation and Toxicity Studies. IIa. Nano-
particle Metabolism. On the basis of the results of
the previous investigations, we can hypothesize that
either (i) AGuIX NPs are eliminated as full native NPs
from the body without any degradation or (ii) they are
degraded in a long, specific process involving the
proximal tubules. We performed mass spectrometry
analysis of mouse urine to elucidate the process of
degradation and evaluate this hypothesis. The urine
was either withdrawn from the bladder to obtain the
first 24 h samples or collected over 24 h beyond this
time (n = 3 minimum/point). The relative intensity of
the total ion signal recorded on the mass spectrometer
ion detector was recorded as a function of time
(Supporting Information, Figure S7). The deconvolution
of the ESI spectra (Figure 7A) revealed two main
distributions of NPs at 8.75 kDa ((320 Da) and
9.6 kDa ((670 Da), as well as several secondary dis-
tributions corresponding to the macromolecules ob-
served at 4 and 7.7 kDa. At low mass (<8 kDa), the
macromolecules, which were identified by their iso-
topic distribution (Supporting Information, Figure S6,
inset), corresponded perfectly with those obtained
from artificially degraded NPs28 and were mainly ob-
served 5 min postinjection of AGuIX NPs before
strongly decreasing with time (Figure 7A). From
5min to 4 weeks post-IV injection, the full native AGuIX
NPs were present in the urine. A mathematical decon-
volution of the mass spectra associated with the NPs
brings to light two distribution masses, one observed
at 8.75 kDa and the second at 9.6 kDa. The smallest NPs
corresponding to 8.75 kDa were eliminated more
rapidly than those constituting the 9.6 kDa population,
as indicated by the decrease in their relative intensities
with time; this result indicates that the elimination of
NPs is related to their mass. After 4 weeks, the very
weak signal measured by mass spectrometry still
corresponded to the signal of the native AGuIX NPs,
indicating that some particles remained in the kidneys.
A comparison of the results obtained by mass
spectroscopy and ICP-OES was performed (Figure 7B).
The relative quantity of AGuIX NPs quantiﬁed in the
urine by mass spectrometry perfectly matched the
quantity of particles measured by ICP-OES when stan-
dardized to 4 h postinjection. Thus, the NPs that enter
the kidney may be excreted in comparable proportions.
Figure 6. TEM images of the distribution of AGuIX NPs in the proximal (left panels) and distal convoluted tubes or glomerular
region (right panels) as a function of elapsed time since a single injection. AGuIX particles are indicated by the arrows. At
2 weeks, few particles remained, and most of the observed regions were vacant. (See also Supporting Information, Figure S6
for a more detailed ﬁgure.)
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During the elimination process, small degraded
particles were eliminated from the body in the ﬁrst
minutes postinjection, whereas full native AGuIX NPs
were entrapped in the proximal convoluted tubules
from a few hours to several days before elimination
from the organism as native AGuIX NPs.
IIb. Evaluation of Safety: Renal Function and Max-
imum Tolerated Dose (MTD). An evaluation of global
toxicity is necessary prior to the clinical application of a
compound. In the present context, the fine evaluation
of renal function is crucial to confirm the absence of
side effects in this major elimination organ. Renal
function was evaluated based on serum creatinine
levels and histological analysis of the kidneys after
different elapsed times post AGuIX administration.
A study of MTD was also conducted to determine the
main observable effects of AGuIX on mice after bolus
injection.
Renal function was ﬁrst evaluated by measuring
serum creatinine concentrations.29,37 As shown in
Table 1, the serum creatinine concentration was signi-
ﬁcantly increased 30 min after NP administration (p =
0.042), but the serum level returned to physiological
levels as soon as 1 h after IV injection, indicating a
transient perturbation that may be attributable to the
bolus injection of the particles.
A histological study of the kidney was then per-
formed after three repeated injections of AGuIX NPs
(1 injection per week for 3 weeks) to determine the
impact of multiple injections on renal function at the
microscopic scale. Standard periodic acid-Schiﬀ (PAS)
staining was used to identify structural modiﬁcations,
the presence of inﬁltrate cells and glomerular ﬁbrosis.
As shown in Figure 8, after three consecutive IV
administrations of AGuIX NPs, some tubular vacuoles
appeared (þ2 weeks). This slight modiﬁcation might
be transient and insigniﬁcant. To assess the reversibil-
ity of this phenomenon and study the long-term
impact of AGuIX NPs administration, kidneys were
collected 4 and 8 weeks after treatment and analyzed
by PAS staining. Neither atrophic tubules nor necrotic
cells were observed in the tubules. Some focal vacuoles
appeared without necrosis but decreased with time
(þ8 weeks). Local abrasion of the brush border (þ2
weeks) was completely repaired after 4 weeks. For
all samples, staining in the glomeruli indicated the
Figure 7. Urine analysis by mass spectroscopy after IV injection of AGuIX NPs. (A) Deconvoluted ESI mass spectra from m/z
spectra of urine samples collected at 5 min, 1 h, and 4 weeks after a single injection of AGuIX NPs, expressed as mass (Da).
(B) Comparison of the relative quantities of AGuIX NPs measured in the urine by mass spectrometry and ICP-AES.
TABLE 1. SerumCreatinine Concentration after a Single Injection of AGuIXNPs (8μmol/mouse), Expressed asmg/L( SDa
control 5 min 30 min 1 h 4 h 24 h 1 week 2 weeks 4 weeks 8 weeks
Creatinine level 8.7 ( 0.5 8.0 ( 1.7 12.7 ( 2.2* 6.5 ( 3.5 7.8 ( 1.8 5.5 ( 0.2 6.4 ( 1.4 7.0 ( 1.3 8.7 ( 0.4 8.5 ( 2.0
a The concentration was measured using the Jaﬀé method and compared to that measured in control mice (n = 3).
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absence of lesions, absence of cell proliferation, and
absence of deposits. At the vessel level, no lesionswere
observed. The interstitial tissue indicated the absence
of ﬁbrosis or edema, a limited number of inﬂammatory
cells (<1%, see also Supporting Information, Figure S8)
and some peritubular dilated capillaries containing
erythrocytes. In summary, the observed modiﬁcations
were slight and transient after three consecutive injec-
tions of AGuIX NPs.
Finally, a speciﬁc study was performed to evaluate
the MTD of AGuIX NPs. AGuIX NPs were IV injected into
six mice per group, and the mice were followed for
10 days to detect any adverse eﬀects (Table 2). For
in vivo applications in mice, the therapeutic dose (TD)
corresponds to an injection of 8 μmol of [Gd3þ]
(a volume of 200 μL at a concentration of 40 mM
[Gd3þ]). The TD is deﬁned as the quantity of Gd per
body mass mostly used in clinical MRI applications.
Increasing doses in the same volume were IV injected
in mice to determine the MTD, which is deﬁned as the
highest single dose of AGuIX NPs that does not cause
any animal fatalities in a group, amaximal weight loss of
10% of total body weight at the end of the experiment,
and the smallest experimental score, as deﬁned in
Table 2. For single doses, no death was observed
10 days after AGuIX NPs injection, maximal weight
losses were less than 10% of total bodyweight, and the
experimental state scores (ESS)were low, even at doses
10-fold higher than the intended safe dose. Thus, a
dose 10-fold higher than the TD could be used before
fatalities occurred. In these experiments, colloidal
AGuIX NP solutions with a concentration of 500 g/L,
the highest concentration at which the particles were
soluble, were injected via a bolus.
These ﬁrst results of the investigations of the safety
of AGuIX NPs indicate promise for translation to the
clinic. The very weak observed eﬀects transiently
altered renal function, as indicated by serum creatinine
levels and the repair of tubular vacuolation within
several weeks after repeated treatment. The MDT in
mice was nearly 10-fold higher than the TD after bolus
injection; slow IV injection may increase tolerance.
Taken together, these results indicate promise for
future regular studies of AGuIX NPs.
DISCUSSION AND CONCLUSION
The 3 nm Gd-based AGuIX NPs were previously
developed and designed for theranostic approaches
in cancer radiotherapy. In parallel with investigations
of eﬃcacy, preliminary in vivo safety studies are re-
quired to determine their pharmacokinetics, elimina-
tion pathway, metabolism, and potential degradation.
The rapid renal elimination of AGuIX NPs after IV
administrations was conﬁrmed and characterized in
this study.2,26,35 The retention of AGuIX NPs in the renal
cortex and their clearance was demonstrated by LIBS
elemental imaging. This innovative method can map
and precisely quantify several elements, including Gd,
one of the main constitutive elements of the particles.
The heterogeneous distribution of Gd in the cortexwas
Figure 8. PAS staining of renal sections after repeated injection of AGuIXNPs (1 injection everyweek for 3weeks). The arrows
indicate tubular vacuoles. The magniﬁcation is indicated at the left bottom corner of each image. Scale bar: 50 μm.
TABLE 2. Determination of the MTD of AGuIX in Non-tumor-bearing Mice after a Single IV Injectiona
dose/inj AGuIX NPs concn experimental state score (ESS) wt variation
μmol/mouse g/L diarrhea lethargy closed eyes diﬃculty waking after anesthesia total % no. of deaths
30 150 0 0 0 0 0 þ3.2 0
40 200 0 0 0 1 1 þ5.4 0
50 250 0 0 0 2 2 þ0.8 0
75 500c 0 0 0 3 3 þ0.5 1b
a The ESS was calculated based on the absence (0) or presence (1) of the evaluated settings. The total ESS was calculated by summing the individual scores. b Death occurred a
few seconds after bolus injection. c Injected volume = 150 μL.
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also determined by a high-deﬁnition investigation
(Figure 3). Intravital two-photon microscopy revealed
fast renal entry of the particles,38 following the ﬁrst
heartbeats. Thismethod also indicated that the highest
uptake occurred 4 h after administration and that
tubular retention was heterogeneous, particularly
48 h after administration (Figure 4). The ﬂuorescent
signal was mainly lost 2 weeks after IV injection,
possibly due to partial degradation of the labeled
particles and consequent dye excretion and/or the
limitation of the technique itself, as some native par-
ticles were still detected by the ICP-OES method.
Spectrometric methods, i.e., ICP-OES and LIBS, con-
ﬁrmed these kinetics but also generated quantitative
information for either the entire kidney or kidney
sections. The ﬁne sensitivity of ICP-OES enabled the
detection of particles several weeks after administra-
tion; only 0.5% of the injected dose was measured in
the kidney 4 weeks after IV injection. These three
methods provided similar but complementary infor-
mation about AGuIX NPs elimination due to their
diﬀerent sensitivities and biological scales.
The comparison of the diﬀerent methods revealed
high standard deviations (SD) for ICP-OES in the ﬁrst
hours after IV administration; this SD might be due to
the presence of particles in the bloodstream or diuresis
(Figure 5). By contrast, the high SD measured by two-
photon microscopy at 48 h post-IV injection demon-
strated the heterogeneity of the distribution of AGuIX
NPs between proximal and distal tubules. Thus, more
than 95% of the particles were eﬃciently eliminated
within the ﬁrst week after IV administration, with
approximately 99% removal after 4 weeks. These rates
of removal are consistent with the pattern of elimina-
tion of other small, silicon-based particles: major elim-
ination in the ﬁrst days and complete elimination after
several weeks.6,7,39,40 We were able to determine pre-
cisely the diﬀerent byproducts excreted from the body
in urine. The ﬁrst excreted products corresponded to
both degraded AGuIX NPs that were most likely biode-
graded after dilution in the bloodstream and entire
particles, whereas only intact particles were released
after a couple of minutes. This pattern of biodegrada-
tion and elimination favors safe elimination of the
compound.
TEM revealed renal accumulation of AGuIX NPs in
the proximal tubules, whereas the distal tubules were
rapidly cleared. The functions of the proximal tubule
cells include the degradation of compounds after
glomerular ﬁltration by exposure to low pH (pH 4 in
lysosomes) and return of the byproducts, consisting of
a piece of polysiloxane surrounded by chelating moi-
ety and Gd, to the bloodstream or elimination through
urine. The long accumulation of AGuIX NPs in these
cells might be explained partially by the high stability
of AGuIX NPs in acidic medium, which prevents their
degradation in lysosomes before their elimination in
urine.41 However, a single bolus injection was very well
tolerated in rodents, even at high concentrations, as
indicated by the MDT assay.
Histological analysis indicated that repeated injec-
tions led to transient vacuolation of the proximal con-
voluted tubules, a phenomenon that was mainly
restored 8 weeks after a 3-week treatment. Renal
tubules have a regenerative capacity;42 however, the
turnover of proximal tubule cells in adult rodents is
very low, and less than 20% of the proximal tubule cells
may regenerate during a 2 week period.43 AGuIX NPs,
which were eﬃciently eliminated, exerted a moderate
and transient eﬀect on proximal cells. The restoration
of the proximal convoluted tubules may be due to self-
repair as well as natural turnover.
To conclude, AGuIX Gd-based NPs, designed for
theranostic applications in radiosensitizing cancer
treatment, are eliminated via the urinary route in a
two-step process involving rapid elimination of biode-
graded and smaller particles and slower elimination of
larger particles. The eﬀect of AGuIX NPs on renal
function was limited to the vacuolation of the proximal
tubules cells; this phenomenon was moderate, transi-
ent, and did not aﬀect renal function itself. All together,
these results indicate the appropriate elimination of
NPs from the organism, which is a prerequisite for the
clinical development of such agents. In this paper, we
combine diﬀerent analytical methods to identify,
image, and quantify the NPs in vivo and ex vivo. The
interest of such a combination of imaging techniques
and analytical measurements may be useful in nano-
medicine with a wide range of materials that may be
distinct from the background, especially for LIBS ima-
ging. In particular, the correlation between analytical
measurements and imaging of the compound of inter-
est appear to be a good standard operating procedure
in nanopharmacology and nanotoxicology, and may
be exploited in diﬀerent organs as amilestone protocol
for distribution, accumulation/elimination, and toxicity
of a wide range of NPs and materials in both physio-
logical and pathological conditions.
MATERIAL AND METHODS
Chemicals and Reagents. The fluorescent dyes used for two-
photon microscopy were fluorescein isothiocyanate (FITC)-
dextran 70-kDa (50 mg/mL in saline, No. FD70S-1G, Sigma-
Aldrich, Saint-Quentin Fallavier France) and Hoechst 34580 (Life
Technologies SAS, Saint Aubin, France). Diethylene glycol (DEG,
99%) was purchased from SDS Carlo Erba (France). DOTAGA
(1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-4,7,10-
triacetic acid) was furnished by Chematech (Dijon, France). Gad-
olinium chloride hexahydrate ([GdCl3, 6 H2O], 99%) and gadoli-
nium oxide cores were furnished by Nano-H S.A.S (Saint-Quentin
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Fallavier, France). Only Elga Purelab Ultra water (F > 18MΩ) was
used to prepare aqueous solutions.
Synthesis of the Gd-Based AGuIX NPs. AGuIX NPs were synthe-
sized as previously described.21 Detailed information can be
found in the Supporting Information.
Relaxometry. Relaxation time measurements were per-
formed using a Bruker Minispec MQ60 NMR analyzer, operating
at 1.4 T magnetic field.
Animals and Ethics. Six- to eight-week-old Balb/c and NMRI
nude mice were purchased from Janvier, France. All mice were
housed in a specific pathogen-free (SPF) environment, and
procedures were performed in accordancewith the Institutional
Animal Care and Use Committee at the University of Lyon and
Grenoble. The research involving animals was authorized under
the agreement number (L. Sancey, Ph.D., permit number 38 09
22 and project in accordance with French Guidelines No.
LS-2013-004). All efforts were made to minimize the number
of animals used and their suffering during the experimental
procedure. Animals were housed in cages with food and water
ad libitum and a 12 h light/dark cycle at 22 ( 1 C.
Anesthetized mice were injected with AGuIX NPs as follows:
single administration, 200 μL at 40 mmol/L; repeated injections
(for the histology study) a similar dose administered once each
week for three weeks.
Laser-Induced Breakdown Spectroscopy. Kidney Sample Prepara-
tion. Mice were initially anesthetized with 4% isoflurane, and
anesthesia was maintained with∼2% isoflurane. Gd-based NPs
(AGuIX, 8 μmol of Gd) were IV injected into the mice under
anesthesia. The kidneys were sampled at various times from
5min to 1week after injection andwere embedded in epoxy, as
described elsewhere.22 In brief, after sampling, each kidney was
perfused and fixed with 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH of 7.4) overnight at room temperature to
preserve both the tissue structure and the distribution of the
particles. The samples were then rinsed three times for 15 min
each in 0.2 M sodium cacodylate buffer. After washing, the
samples were dehydrated in a series of ethanol solutions of
increasing concentration, ending with propylene oxide. The
samples were then embedded in EPON (1:1 mixture of diglyci-
dyl ether and dodecenylsuccinic anhydride, density of 1.22 g/L).
The sample surfaces were prepared using a microtome. For
elemental quantification, standards containing AGuIX NPs were
embedded in the same EPON resin, at five concentrations
ranging from 1 to 40 mM. The powders were mixed with the
resin (for a minimum of 4 h), warmed for 2 days (60 C), and
finally prepared using a microtome.
LIBS Settings. The instrumental setupwas based on a home-
made optical microscope that combined a LIBS laser injec-
tion line, a standard optical-imaging apparatus, and a three-
dimensional motorized platform for sample positioning. The
LIBS experiment has been described elsewhere,35 and only its
main features are described in the following. Quadruple Nd:YAG
laser pulses of 266 nm with a duration of 5 ns and a 10 Hz
repetition rate were focused onto the sample by a high-power
15magnification objective (LMU-15X-266, Thorlabs). During the
experiments, the sample was translated along 2 axes by an XY
motorized stage. The measurements were performed at room
temperature with argon gas flowing through the plasma region.
During the sample scan, trigonometric surface positioning was
used to compensate for any flatness anomalies and to accu-
rately control the focalization distance (the objective-to-sample
distance). A beam shutterwas used to control the delivery of the
laser pulse to the sample such that only one plasma plume was
produced for each position in the sample. The light emitted by
the plumewas collected by a quartz lens with a focal distance of
2 cm and focused onto the entrance of an optical fiber bundle.
The output of the fiber bundle was connected to a Czerny
Turner spectrometer equipped with a 1200-L/mm grating
blazed at 300 nm and an intensified charge-coupled device
(ICCD) camera (Shamrock 303 and iStar, Andor Technology). The
ICCD camera was synchronized with the Q-switch of the laser,
and the spectrum acquisition was performed with a delay of
300 ns and a gate of 3 μs. A spectral measurement range of
typically 30 nm was accessible with a spectral resolution of
approximately 0.15 nm. The laser energy was stabilized
throughout the experiment using a servo control loop to ensure
the long-term stability of the laser output. Customized software
developed in the LabVIEW environment controlled the entire
system and enabled the performance of automated sequences
to scan the region of interest of the tissue sample with a specific
lateral resolution.30
Intravital Microscopy;Two-Photon Microscopy. Two-photonmicros-
copywas performed using a LSM7MP (Zeiss, Germany) equipped
with a 20 water-immersion objective (NA 1.0; Zeiss) and ZEN
2010 software. Laser excitationwas performed at 800 nmwith a Ti:
sapphire laser (Chameleon vision II; Coherent,UK) usinga constant
laser power of approximately 60 mW. Fluorescence emissions
were detected simultaneously by three nondescanned photo-
multiplier tubes with a 492/SP25 nm filter (Semrock, US) for ''blue”
fluorescence emission, a 542/50 nm filter (Semrock, US) for
“'green'” fluorescence emission, and a 617/73 nm filter
(Semrock, US) for “'red'” fluorescence emission (Rhodamine B).
Theblue andgreen channelswere collected for specific labelingof
the nucleus (Hoechst 34580) and blood vessels (FITC (fluorescein
isothiocyanate)Dextran), respectively. Autofluorescence and
second harmonic generation of biological structures could also
be collected in the three channels owing to the presence of
collagen, lectin, and elastin.
During in vivo two-photon microscopy, animals were anes-
thetized with 12% isoﬂurane in a 70% air, 30%O2 gas mixture.
Body temperature was maintained at 37 C using a heating
blanket. A small incision was made in the mouse's back to
expose the kidney. After imaging the kinetic elimination of
AGuIX NPs for 1 or 2 h, a mixture of FITCdextran and Hoechst
was IV injected. Ten minutes later, the kidney was removed
either for ex vivo imaging or chemical ﬁxation and/or freezing in
pentobarbital, followed by storage in liquid nitrogen until
further analysis.
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES)
Analysis. ICP-OES analysis was used to determine the Gd content
in both the NPs themselves and the kidneys. After a single
injection of mice with AGuIX NPs, the kidneys were dispersed in
5mL of aqua regia (67% HNO3/37% hydrochloric acid (w/w)) for
4 h at 80 C. Subsequently, the samples were diluted with a
HNO3 5% (w/w) matrix to adjust the volume to 10 mL; the
sampleswere then filtered (0.22μm) and analyzed by ICP-OES at
the lab or at the “Service Central d'Analyses du CNRS” (Solaize,
France) to determine the elemental content with a precision of
2%. For calibration of the ICP-OES, single-element standard
solutions were prepared by successive dilution in a HNO3 5%
(w/w) matrix from a 1000-ppm Gd standard acquired from SCP
Science. Importantly, for comparison with the LIBS experiment,
the right kidney of each animal was sectioned for imaging, and
the left kidney of the same animal was used for ICP-OES.
Transmission Electron Microscopy. Sampled kidneys were fixed
as described previously or LIBS analysis and postfixed in 1%
osmium tetroxide in 0.1 M sodium cacodylate buffer for 1 h.
After washing, the samples were dehydrated in an ethanol
series of increasing concentrations, ending with propylene
oxide. The samples were then embedded in EPON (1:1 mixture
of diglycidyl ether and dodecenylsuccinic anhydride). Thin
sections of approximately 70 nmwere prepared with a Reichert
Ultracut E ultramicrotome. The sections were observed using a
Philips CM120 electron microscope operating at 120 kV.
Electrospray Ionization (ESI) Mass Spectrometry. Full-scan mass
spectra were obtained using a linear quadruple ion trap mass
spectrometer (LTQ, Thermo Fisher Scientific, San Jose, CA) with
enlargement for the high 20004000 Th range. The NP solution
was electrosprayed at a flow rate of 20 μL/min in positive ion
mode.
Two diﬀerent tunes were used: one for high mass observa-
tion (Tune 1 between 200 m/z and 4000 m/z) and the other for
lowmass (Tune 2 between 150m/z and 2000m/z). The lowmass
tune allowed us to study AGuIX fragments. Isotopic distribu-
tions of fragment ions were recorded using the zoom scan
mode of the LTQ ion trap mass spectrometer. Because AGuIX
NPs contain multiple groups capable of being ionized (e.g.,
Gd-DOTA complexes), the ESI source can produce highly
charged ions. For those macromolecules that can sustain multi-
ple charges, a distribution of charge states is often observed in
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the mass-to-charge spectrum. This multiplicity of states gives
rise to an “envelope” of peaks in the spectrum. Such a distribu-
tion of charges was observed in them/z range 10004000 after
electrospraying in positive mode a water solution containing
AGuIX NPs. A multiplicative correlation algorithm (MCA) was
used to estimate the mass of the NPs from the mass-to-charge
spectra produced by ESI-MS.44 The multiplicative correlation is
designed to enhance the deconvoluted signal when the parent
molecule is distributed into several charge states in the mea-
sured spectrum.
Creatinine Level. Total blood samples were collected from the
right ventricular cavity. The serumwas separatedbycentrifugation
at 3000g for 10 min at 4 C, and the creatinine concentration
was analyzed according to the manufacturer's instructions
(Bio-Merieux, Marcy l'Etoile, France). Briefly, 2-point kinetics mode
was used to measure the red-orange complex formed with picric
acid in alkaline medium according to the Jaffe method. In vivo
TPLSM imaging was performed at the Two-Photon Microscopy
Platform (GIS-IBiSA ISdV, Photonic Imaging Center - Grenoble
Institute of Neuroscience). Measurements were obtained with a
50 scan UVvisible spectrophotometer (Varian Cary Eclipse).
Maximal Tolerated Dose. Groups of six mice received a single
bolus injection of AGuIX NPs at doses ranging from 30 to
75 μmol, that is, a single IV injection of 150 to 200 μL at
concentrations from 150 to 500 g/L. After being injected, the
mice were weighed and observed every day to evaluate the
general clinical state. For each animal, a score was calculated
based on the absence (value 0) or presence (value 1) of diarrhea,
lethargy, closed eyes, and difficulty waking after anesthesia. An
experimental state score (ESS) was then calculated for each
group by summing the individual scores. Loss of weight and
mortality were also recorded. The MTD was defined as the
highest single dose thatmet all of the following criteria: absence
of death in the group, maximal weight loss of 10% in nontumor-
bearing animals, and ESS value as low as possible.
Histology. Histology was performed on kidney samples after
repeated injections of AGuIX NPs(1 injection/week for 3 weeks).
Kidneys were sampled at the indicated time after injection.
Kidneys were then fixed in a Japanese fixative at 4 C for a
minimum of 1 h; next, kidneys were washed in cacodylate
sodium, dehydrated in pure acetone, and incubated in glycol-
methacrylate (GMA) for 3 h before embedding in GMA contain-
ing 0.8% aniline propanol. Japanese fixative is a solution of 6%
paraformaldehyde, 8.5% sodium cacodylate, 0.073% calcium
chloride, and 0.2% picric acid, adjusted at pH 7.4.
Resin sections with a thickness of 2 μm were prepared and
stainedwith periodic acid-Schiﬀ (PAS) using standard protocols.
Brieﬂy, 2-μm slides were treated with 0.5% periodic acid for
10 min, washed with water, colored with Schiﬀ stain for 20 min,
rinsed again with water, and then counter-stained with Harris
hematoxylin for 30 min. Sections were mounted with resinous
mounting medium.
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